Hydralazine
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Hydralazine
Description:
Hydralazine is a orally active antihypertensive agent, reduces peripheral resistance directly by relaxing the smooth muscle cell layer in arterial vessel. Hydralazine has antioxidant activity, as well as inhibits reactive oxygen species (ROS) release and O2·- generation with an IC50 value of 9.53 mM and 1.19 mM, respectively[1][2].UNSPSC:
12352005Hazard Statement:
H302, H312, H332Target:
Reactive Oxygen Species (ROS)Type:
Reference compoundRelated Pathways:
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κBApplications:
COVID-19-immunoregulationField of Research:
Inflammation/Immunology; Cardiovascular Disease; CancerAssay Protocol:
https://www.medchemexpress.com/hydralazine.htmlPurity:
99.9400Solubility:
DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)Smiles:
N/N=C1NN=CC2=C\1C=CC=C2Molecular Formula:
C8H8N4Molecular Weight:
160.18Precautions:
H302, H312, H332References & Citations:
[1]Arce C, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Candelaria M, Dueñnas-Gonzalez A. Hydralazine target: from blood vessels to the epigenome. J Transl Med. 2006 Feb 28;4:10.|[2]Leiro JM, et al. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int Immunopharmacol. 2004 Feb;4 (2) :163-77.Shipping Conditions:
Blue IceStorage Conditions:
-20°C, 3 years (Powder)Scientific Category:
Reference compound1Clinical Information:
LaunchedCitation 01:
J Pharm Anal. 2024 Jan;14 (1) :86-99.|Microchem J. 2025 Nov 24;220:116331.|Neurosci Bull. 2020 Oct;36 (10) :1158-1170.CAS Number:
[86-54-4]
